Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 282-810-6 | CAS number: 84434-11-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08 February 2013 - 25 April 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted Oct. 2008
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- adopted May 2008
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Ethyl phenyl(2,4,6-trimethylbenzoyl)phosphinate
- EC Number:
- 282-810-6
- EC Name:
- Ethyl phenyl(2,4,6-trimethylbenzoyl)phosphinate
- Cas Number:
- 84434-11-7
- Molecular formula:
- C18H21O3P
- IUPAC Name:
- ethyl phenyl(2,4,6-trimethylbenzoyl)phosphinate
- Details on test material:
- - Name of test material (as cited in study report): Lucirin TPO-L
- Physical state: Liquid, viscous /yellow, clear
- Analytical purity: >97.8%
- Lot/batch No.: Mischung 120204
- Expiration date of the lot/batch: May 29th, 2015
- Storage condition of test material: Room temperature; under light exclusion
- Stability under test conditions: analysis confirmed stability for 96h of the test substance preparations at room temperature
Constituent 1
- Specific details on test material used for the study:
- Purity: 95.7 g/100g (by quanitative H-NMR; study No. 13L00016)
Homogeneity: given
Stability: The stability of the test substance under storage conditions over the test period was guaranteed by the sponsor, and the sponsor holds this responsibility.
Physical state/ appearance: liquid, viscous/ yellow, clear
Storage conditions: ambient (room temperature); under light exclusion
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- The rat is a frequently used laboratory animal, and there is comprehensive experience with this animal species.
Moreover, the rat has been proposed as a suitable animal species by the OECD and the EPA for this type of study. - Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services GmbH, Sulzfeld, Germany
- Age at study initiation: 41-43 days
- Weight at study initiation: not reported
- Fasting period before study: no
- Housing: groups of 5 in polysulfonate cages (floor area 2065cm²)
- Diet (e.g. ad libitum): ground Kliba maintenance diet mouse/rat “GLP”, meal ad libitum
- Water (e.g. ad libitum): ad lib.
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24°C
- Humidity (%): 30-70%
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12h/12h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 1% in water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Test substance emulsions were prepared at least twice a week by stirring the appropriate amount in water containing 1% CMC. During administration of the test substance, preparations were kept homogeneous by stirring with a magnetic stirrer.
- Concentration in vehicle: 0.5, 1,5, 5.0g/100mL
- Volume used: 10ml/kg - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Homogeneity was verified in the highest and lowest concentration. Correctness of concentration was confirmed in all concentrations at the beginning of the study. All measured values were in the range of 95 - 105%.
The analyses of the test substance preparations were carried out at the Analytical Chemistry Laboratory of Experimental Toxicology and Ecology of BASF SE, Ludwigshafen, Germany. The studies were carried out in compliance with the Principles of Good Laboratory Practice.
The stability of Lucirin TPO-L in water at room temperature for a period of 96 hours was demonstrated (project No. 01Y0459/038023; see PART III, Supplement).
Homogeneity of Lucirin TPO-L was verified in the highest and lowest concentration. Additionally, concentration control was verified in all concentrations at the beginning of the study.
See attached background material for more detail - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- DOSE SELCTION RATIONALE
In a test study 3 male and 3 female Wistar rats were treated with 1000mg/kg b.w. (BASF project No. 10C0459/03S008). The animals showed clear signs of systemic toxicity like poor general condition, piloerection, hunched posture and impaired body weight parameters. 2 females were sacrificed moribund on day 6. At scheduled necropsy on day 14, increased liver weights (absolute: males: 184%; females: 233% and relative: males: 221%; females: 223%), increased absolute (males: 111%; females: 140%) and relative (males: 135%; females: 134%) kidney weights, and increased adrenal gland and decreased spleen weights were observed in both genders.
Another set of male animals treated for 7 days with 500 mg/kg bw/d showed no clinical signs of concern, but liver weights were also increased, i.e. absolute (127%) and relative (121%) and spleen weights were decreased.
Based on these findings, 500mg/kg was chosen as the maximum dose level in the main study. - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily before administration as well as 2-5h after administration
- The following observations were included: mortality, clinical signs
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at weekly intervals starting on day 0 prior to administration
- The following observations were recorded in a standard arena: abnormal behavior when handled, fur, skin, posture, salivation, respiration, activity/arousal level, tremors, convulsions, abnormal movements, impairment of gait, lacrimation, palpebral closure, exophthalmus, appearance/consistency of feces, urine, pupil size
BODY WEIGHT: Yes
- Time schedule for examinations: weekly starting on day 0
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes (at weekly intervals over a period of one day)
WATER CONSUMPTION: Yes
- Time schedule for examinations: monitored daily by visual inspections of water bottles
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at necropsy (day 29)
- Animals fasted: Yes (at least for 16h, water available ad lib.)
- How many animals: all
- Parameters examined: Leucocyte count, erythrocyte count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, differential blood count, reticulocytes, prothrombin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at necropsy (day 29)
- Animals fasted: Yes (at least for 16h, water available ad lib.)
- How many animals: all
- Parameters examined: ALT, AST, ALP, GGT, sodium, potassium, chloride, inorganic phosphate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, bile acids
URINALYSIS: Yes
- Time schedule for collection of urine: on day 23
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes (no food or water provided)
- Parameters examined: pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, specific gravity, sediment, color, turbidity, volume
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: at the end of the administration period (days 25/26)
- Dose groups that were examined: all
- Battery of functions tested: home cage observations in single animal cages, open field observations, sensory motor tests / reflexes, motor activity
OTHER:
- Oestrus cycle determination: vaginal smears were prepared in the morning for at least 3 weeks and at necropsy
- Sperm parameters: sperm motility, sperm morphology, sperm head count (cauda epididymis and testis) - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Organ weights: anesthetized animals, adrenal glands, brain, epididymides, heart, kidneys, liver, ovaries, prostate, seminal vesicles with coagulating glands, spleen, testes, thymus, thyroid glands, uterus with cervix
histopathologic examinations:
all animals: adrenal glands, left epididymis, kidneys, liver, spleen, stomach, testis
all high dose and control animals: bone marrow (femur), brain, cecum, cervix, coagulating glands, colon, duodenum, eyes with optic nerve, heart, ileum, jejunum, lung, lymph nodes, ovaries, peyer's patches, pituitary glands, prostate, rectum, sciatic nerve, seminal vesicles, skeletal muscle, spinal cord, sternum, thymus, thyroid glands, trachea, urinary bladder, uterus, vagina
Gross lesions were examined in all animals affected. - Other examinations:
- All observations made reported in attached background material
- Statistics:
- BODY WEIGHT, BODY WEIGHT CHANGE
A comparison of each group with the control group was performed using DUNNETT's test (two-sided) for the hypothesis of equal means
* for p ≤ 0.05
** for p ≤ 0.01
DUNNETT, C.W. (1955): A multiple comparison procedure for comparing several treatments with a control. JASA, Vol. 50, 1096-1121
DUNNETT, C.W. (1964). New tables for multiple comparisons with a control. Biometrics, Vol. 20, 482-491
Feces, rearing, grip strength forelimbs, grip strength hindlimbs, foot-splay test, motor activity, umber of cycles, cycle length
Non-parametric one-way analysis using KRUSKAL-WALLIS test (two-sided). If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using WILCOXON test (two-sided) for the equal medians
* for p ≤ 0.05
** for p ≤ 0.01
SIEGEL, S. (1956): Non-parametric statistics for the behavioural sciences. McGraw-Hill New York
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Salivation was observed in all high dose animals and most mid dose female animals shortly after treatment on several days throughout the study, starting on day 1. From the temporary, short appearance immediately after dosing it was concluded that salivation was induced by a bad taste of the test substance or local affection of the upper digestive tract.
(Tables IIA- 1 - IIA-24) - Mortality:
- no mortality observed
- Description (incidence):
- No animals died prematurely.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No test substance-related changes in body weight or body weight gain were observed for male and female animal of test groups 1-3 (50, 150 and 500 mg/kg bw/d) when compared to control groups.
The significantly decreased body weight change value in female animals of test group 2 (150 mg/kg bw/d) on study day 7 was assessed as being incidental and not related to treatment.
(Tables IIA-27 - IIA-28) - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No test substance-related, adverse findings were observed in male and female animals of test groups 1-3 (50, 150 and 500 mg/kg bw/d).
(Tables IIA-25 - IIA-26) - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- Drinking water consumption was monitored by daily visual inspection of the water bottles for any changes in volume. No overt changes in volume were observed.
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes among hematological parameters were observed.
Regarding red blood cell parameters, in male animals of test group 3 (500 mg/kg bw/d) mean corpuscular volume (MCV) was lower, and in females of the same test group relative reticulocyte counts were higher compared to controls. However, both parameters were within historical control ranges (males: MCV 48.1-53.7 fL, females: relative reticulocyte counts 1.0-4.9%; PART III, Supplement). Therefore, these alterations were regarded as incidental and not treatment-related.
In male animals of test groups 1 and 3 (50 and 500 mg/kg bw/d) absolute monocyte counts were decreased, although not dose-dependently, and in males of test group 3 (500 mg/kg bw/d) relative monocyte counts were lower compared to controls. However, all medians were within historical control ranges (absolute monocyte counts 0.05-0.19 Giga/L; relative monocyte counts 0.9-2.5%; PART III, Supplement). Therefore, both changes were regarded as incidental and not treatment-related.
(Tables IB 1 – IB 2 Red blood cell and coagulation parameters)
(Tables IB 3 – IB 4 White blood cell parameters) - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related, adverse changes among clinical chemistry parameters were
observed.
At the end of the administration period, in male animals of test group 1 (50 mg/kg bw/d) inorganic phosphate levels were increased. In female animals of test group 1 and 2 (50 and 150 mg/kg bw/d) creatinine levels were increased. However, both parameters were not changed dose-dependently and therefore the alterations were regarded as incidental and not treatment-related.
In males of test group 3 (500 mg/kg bw/d) cholesterol concentrations were decreased and in females of the same test group triglyceride and inorganic phosphate levels were increased. The inorganic phosphate levels in females were within the historical control range (phosphate 1.46-2.24 mmol/L; PART III, Supplement). The decreased cholesterol levels in males and increased triglyceride levels in females of test group 3 (500 mg/kg bw/d) were isolated in either sex and, therefore, they were regarded as treatment-related but not adverse (ECETOC Technical Report No 85, 2002).
(Tables IB 5 – IB 6 Enzymes)
(Tables IB 7 – IB 8 Substrates)
(Tables IB 9 – IB 10 Electrolytes + minerals) - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related, adverse changes among urinalysis parameters were observed. Higher urobilinogen levels in the urine were measured in high dose rats of both sexes and, additionally, in mid dose males. Urobilinogen is synthesized in the intestine by bacteria and absorbed by the gut into the blood. With the blood circulation it normally enters the liver and is re-excreted via bile into the intestine. When a higher amount of urobilinogen is produced because of a greater breakdown of hemoglobin during hemolytic anemia, or a liver damage and cholestasis is preventing the biliary excretion of urobilinogen, higher amounts of the molecule are excreted via the kidneys.
However, in this study there was neither any indication of an anemia nor any sign of a liver cell damage or cholestasis. It is highly probable that the indicator field of the urobilinogen test strip is falsely affected by renal excreted compound or its metabolites coloring the urine light pastel orange. Therefore, because it was an isolated finding not accompanied by any red blood cell or liver cell alteration this change was regarded as treatment-related but not adverse (ECETOC Technical Report No 85, 2002).
(Tables IB 11 – IB 14) - Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean absolute and relative liver and kidney weights (in females only the relative kidney weight was increased) were significantly increased in high dose animals above current and historical control data (app. 140% for liver, 120% for kidney)
The liver and kidneys weight increases in males and the liver weight increase in females of test group 3 (500 mg/kg bw/d) were regarded as treatment-related. The liver weight increase in males (7.698 g) and females (4.864 g) of test group 2 (150 mg/kg bw/d) was within the range of the historical control data (males: 6.486-8.468 g; females: 4.194-5.426 g; PART III, Supplement). Therefore, the latter change was not considered to be treatment-related.
All other mean absolute weight parameters did not show significant differences when compared to the control group 0.
The liver weight increases in males and females of test group 3 (500 mg/kg bw/d) correlated with histopathological findings and were regarded as treatment-related. Although the kidney weight increase of males and females in test group 3 (500 mg/kg bw/d) had no histopathological correlate, it was regarded as treatment-related but not adverse. The liver weight increase in males (2.893%) and females (2.868%) of test group 2 (150 mg/kg bw/d) showed no histopathological correlate and were within the range of the historical controldata (males: 2.505-3.223%; females: 2.472-3.208%) and, therefore, were not considered to be treatment-related. All other mean relative weight parameters showed no significant differences when compared to the control group 0.
(Tables IC 1 – IC 8) - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In test group 3 (500 mg/kg bw/d), 2 out of 5 males and 3 out of 5 females showed dark discoloration of the liver. However, no histopathological correlate was observed for this macroscopic finding. All other findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
(Tables IC 9) - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Correlating to the increased liver weights, minimal to slight centrilobular liver hypertrophy was observed in males (grade 2) and females (grade 1) of the high dose group. This finding was considered treatment related, but adaptive and not adverse. No histopathological correlate was found for the absolute and/or relative kidneys weight increase in males and females of this test group. However, this change was not considered to be adverse and most likely reflects an adaptive effect.
(Tables IC 10 – IC 13) - Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- Length and number of estrous cycle was unaffected.
(Table IA-45)
Sperm motility, sperm head counts, and incidence of abnormal sperms were unaffected by treatment.
(Tables IB 15) - Details on results:
- Lucirin TPO-L was administered orally by gavage to groups of 5 male and 5 female Wistar rats at dose levels of 0 mg/kg bw/d (test group 0), 50 mg/kg bw/d (test group 1), 150 mg/kg bw/d (test group 2) and 500 mg/kg bw/d (test group 3) over a period of 4 weeks.
Clinical examinations did not reveal treatment-related, adverse effects up to a dose level of 500 mg/kg bw/d. In addition, no test substance-related effects on estrous cycle length and the number of estrous cycles were obtained.
Salivation after treatment was seen in all animals of test group 3 (500 mg/kg bw/d) and sporadically in a few female animals of test group 2 (150 mg/kg bw/d). From the temporary, short appearance immediately after dosing it is likely, that this finding was induced by a bad taste of the test substance or local affection of the upper digestive tract. This finding was not considered to be an adverse and toxicologically relevant effect.
Concerning clinical pathology, no treatment-related, adverse effects were observed up to a dose of the compound of 500 mg/kg bw/d.
Regarding pathology, the absolute and/or relative weight increases observed in the liver and the kidneys of male and female animals of test group 3 (500 mg/kg bw/d) were regarded as treatment-related. In the liver, the weight increase correlated with centrilobular hepatocellular hypertrophy, affecting 5 out of 5 males (slight) and 4 out of 5 females (minimal). As the hepatocellular hypertrophy occurred without histopathological or clinical pathology alterations indicative of liver toxicity, the liver findings were considered to be treatment-related but adaptive and were therefore regarded as non-adverse (Hall et al., 2012). No histopathological correlate was found for the absolute and/or relative kidneys weight increase in males and females of test group 3 (500 mg/kg bw/d). However, this change was not considered to be adverse and most likely reflects an adaptive effect.
All other findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The oral administration of the test substance by gavage over a period of 4 weeks did not reveal signs of systemic toxicity in male and female Wistar rats up to a dose level of 500 mg/kg bw/d. In addition, no changes with regard to the reproductive organs were observed. Therefore, under the conditions of the present study, the no observed adverse effect level (NOAEL) was 500 mg/kg bw/d for male and female Wistar rats.
- Executive summary:
METHODS
Lucirin TPO-L was administered orally by gavage to groups of 5 male and 5 female Wistar rats at dose levels of 0 mg/kg body weight/day (mg/kg bw/d; test group 0), 50 mg/kg bw/d (test group 1), 150 mg/kg bw/d (test group 2) and 500 mg/kg bw/d (test group 3) over a period of 4 weeks.
OBSERVATIONS
Food consumption and body weight were determined weekly. The animals were checked daily for any abnormal clinical signs before the administration as well as within 2 hours and within 5 hours after the administration. Detailed clinical examinations in an open field were conducted prior to the start of the administration period and weekly thereafter. Beside this, a functional observational battery (FOB) as well as measurement of motor activity (MA) were carried out towards the end of the administration period.
Clinicochemical and hematological examinations as well as urinalyses were performed towards the end of the administration period. After the administration period all rats were sacrificed and assessed by gross pathology, followed by histopathological examinations. In addition to the required examinations, special attention was given to the reproductive organs of male and female animals, i.e. for at least 3 weeks an estrous cycle determination was performed and sperm parameters were examined after necropsy.
RESULTS
Analytics
The various analyses confirmed the stability of the test-substance preparations for a period of 96 hours at room temperature the homogeneous distribution of the test article in the vehicle, the correctness of the prepared concentrations.
Findings
The following test substance-related, relevant findings were noted:
Test group 3: 500 mg/kg bw/d
Clinical Examinations, Clinical Pathology and Pathology4
No treatment-related, adverse effects were observed.
Test group 2: 150 mg/kg bw/d
Clinical Examinations, Clinical Pathology and Pathology
No treatment-related, adverse effects were observed.
Test group 1: 50 mg/kg bw/d
Clinical Examinations, Clinical Pathology and Pathology
No treatment-related, adverse effects were observed.
CONCLUSION
The oral administration of Lucirin TPO-L by gavage over a period of 4 weeks did not reveal signs of systemic toxicity in male and female Wistar rats up to a dose level of 500 mg/kg bw/d. In addition, no changes with regard to the reproductive organs were observed. Therefore, under the conditions of the present study, the no observed adverse effect level (NOAEL) was 500 mg/kg bw/d for male and female Wistar rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
